HCPCS Code Detail Logo

HCPCS Codes Similar to S3852

HCPCS Codes Similar to “S3852” Code.
Dna analysis for apoe epsilon 4 allele for susceptibility to alzheimer's disease

G2178
Clinician documented that patient was not an eligible candidate for lower extremity neurological exam measure, for example patient bilateral amputee; patient has condition that would not allow them to accurately respond to a neurological exam (dementia, alzheimer's, etc.); patient has previously documented diabetic peripheral neuropathy with loss of protective sensation
Code added date: 20210101
Code effective date: 20210101
S3840
Dna analysis for germline mutations of the ret proto-oncogene for susceptibility to multiple endocrine neoplasia type 2
Code added date: 20030701
Code effective date: 20030701
S3843
Dna analysis of the f5 gene for susceptibility to factor v leiden thrombophilia
Code added date: 20030701
Code effective date: 20120401
S3844
Dna analysis of the connexin 26 gene (gjb2) for susceptibility to congenital, profound deafness
Code added date: 20030701
Code effective date: 20030701
S3820
Complete brca1 and brca2 gene sequence analysis for susceptibility to breast and ovarian cancer
Code added date: 20030401
Code effective date: 20120401
S3822
Single mutation analysis (in individual with a known brca1 or brca2 mutation in the family) for susceptibility to breast and ovarian cancer
Code added date: 20030401
Code effective date: 20120401
S3823
Three-mutation brca1 and brca2 analysis for susceptibility to breast and ovarian cancer in ashkenazi individuals
Code added date: 20030401
Code effective date: 20120401
S3833
Complete apc gene sequence analysis for susceptibility to familial adenomatous polyposis (fap) and attenuated fap
Code added date: 20030401
Code effective date: 20140101
S3834
Single-mutation analysis (in individual with a known apc mutation in the family) for susceptibility to familial adenomatous polyposis (fap) and attenuated fap
Code added date: 20030401
Code effective date: 20140101
S3890
Dna analysis, fecal, for colorectal cancer screening
Code added date: 20040401
Code effective date: 20160101
U0003
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r
Code added date: 20200414
Code effective date: 20230512
U0005
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2
Code added date: 20210101
Code effective date: 20230512
M1194
Documentation of medical reason(s) surgical pathology reports did not contain impression or conclusion of or recommendation for testing of mmr by immunohistochemistry, msi by dna-based testing status, or both tests were not included (e.g., patient will not be treated with checkpoint inhibitor therapy, no residual carcinoma is present in the sample [tissue exhausted or status post neoadjuvant treatment], insufficient tumor for testing)
Code added date: 20230101
Code effective date: 20230101
G0545
Visit complexity inherent to hospital inpatient or observation care associated with a confirmed or suspected infectious disease by an infectious diseases specialist, including disease transmission risk assessment and mitigation, public health investigation, analysis, and testing, and complex antimicrobial therapy counseling and treatment (add-on code, list separately in addition to hospital inpatient or observation evaluation and management visit, initial, same day discharge, subsequent or discharge)
Code added date: 20250101
Code effective date: 20250101